by Lengea Law | Mar 23, 2024 | Starting a Business
The medical spa business in the United States has experienced exponential growth in the past few years, and Texas is no exception. Technological innovations in the treatments provided at med spas have increased patient satisfaction by reducing recovery times and...
by Lengea Law | Nov 1, 2023 | Finance & Tax Planning
Abbvie, the maker of Botox and the Juvederm collection of fillers, has reported less-than-expected third-quarter 2023 financial results. What does this mean for your practice? You may also be experiencing lower-than-projected revenue, but your expenses have yet to go...
by Lengea Law | Sep 21, 2023 | News
Daxxify is a new FDA-approved neuromodulator by Revance Therapeutics (“Revance”) designed to soften the look of fine lines and wrinkles. Daxxify differs from Botox and other botulinum toxin injectables, like Xeomin, Juveau, and Dysport, in that it is designed to work...
by Lengea Law | Sep 19, 2022 | Finance & Tax Planning
This month’s biggest story in the med spa industry is the FDA’s approval of Daxxify. Is this the best thing since Botox or is it just another fall fad? The Lengea team cuts through the hype and tells you what it really means for your practice. What is Daxxify? The New...
